読み込み中
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
前日終値
$6.83
−$0.38 · -5.27%
市場前
$7.07
+$0.24 · +3.51%
10月14日 9:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
日中レンジ
現在 $6.83
52週レンジ
現在 $6.83
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
43
まちまち
リスク
55
やや高いリスク
モメンタム
37
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
日中レンジ
現在 $6.83
52週レンジ
現在 $6.83
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4826.6万 EUR | 1.56億 EUR | 5399.7万 EUR | 1.73億 EUR | 3476.3万 EUR |
| 粗利益 | 4826.6万 EUR | 1.56億 EUR | 5399.7万 EUR | 1.73億 EUR | 3476.3万 EUR |
| 研究開発 | 1.84億 EUR | 1.48億 EUR | 1.19億 EUR | 1.07億 EUR | 8757.4万 EUR |
| 販売・一般管理 | 5118.4万 EUR | 4644.9万 EUR | 3819.8万 EUR | 3612.4万 EUR | 3380.8万 EUR |
| 営業費用 | 2.3億 EUR | 1.94億 EUR | 1.56億 EUR | 1.43億 EUR | 1.21億 EUR |
| 受取利息 | 1717.9万 EUR | 2500.1万 EUR | 1384.5万 EUR | 247.6万 EUR | 13.3万 EUR |
| 支払利息 | 94.6万 EUR | 88.6万 EUR | 83.1万 EUR | 103.8万 EUR | 56.6万 EUR |
| 減価償却費と償却費 | 1240万 EUR | 1222.5万 EUR | 723.4万 EUR | 696.7万 EUR | 526万 EUR |
| 営業利益 | −1.82億 EUR | −3861.5万 EUR | −1.02億 EUR | 2995.4万 EUR | −8629.4万 EUR |
| 純利益 | −1.96億 EUR | 1521.8万 EUR | −9464.9万 EUR | 2770.3万 EUR | −9333.5万 EUR |
会社概要が更新されました 2026年10月14日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR Portfolio Developed World ex-US ETFSPDW141.46万0.00%406.43億 USD0.03%$49.78+0.19%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP132.12万0.05%25.91億 USD0.20%$65.01-0.38%
ALPS Medical Breakthroughs ETFSBIO129.8万0.72%1.79億 USD0.50%$51.64-4.10%
Tema Oncology ETFCANC99.83万0.50%2.03億 USD0.99%$39.2603-3.25%
Fidelity Nasdaq Composite Index ETFONEQ43.86万—109.4億 USD0.21%$107.2-0.15%
State Street SPDR S&P International Small Cap ETFGWX40.86万0.04%9.1億 USD0.40%$45.30+0.09%
Virtus Biotech Clinical Trials ETFBBC24.39万0.60%3876.9万 USD0.65%$40.64-5.61%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED23.77万0.73%3215.55万 USD0.44%$33.0069-1.87%State Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR S&P Kensho New Economies Composite ETFKOMPALPS Medical Breakthroughs ETFSBIOTema Oncology ETFCANCFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P International Small Cap ETFGWXVirtus Biotech Clinical Trials ETFBBCT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
